PD-L2/CD273 Polyclonal antibody 18251-1-AP proteintech

$149.00
In stock
SKU
18251-1-AP
Catalog No.SizePrice (USD)
18251-1-AP-20UL20 μL$149.00
18251-1-AP-150UL150 μL$449.00
Catalog Number18251-1-AP
SynonymsB7 DC, Btdc, Butyrophilin B7 DC, CD273, PD 1 ligand 2, PDCD1 ligand 2, PDCD1L2, PDCD1LG2, PDL2, PD-L2, PD-L2/CD273, Programmed death ligand 2
HostRabbit
Reactivityhuman, mouse, rat
FormLiquid
FormulationPBS, Azide, Glycerol
ApplicationsWB, IHC, ELISA
ApplicationsWB, ELISA
Host / IsotypeRabbit / IgG
Tested Applications — Positive WB detected inNIH/3T3 cells, mouse heart tissue, HepG2 cells, RAW 264.7 cells
Recommended Dilutions — Western Blot (WB)WB : 1:500-1:2000
Positive WB detected inNIH/3T3 cells, mouse heart tissue, HepG2 cells, RAW 264.7 cells
Western Blot (WB)WB : 1:500-1:2000
Tested Reactivityhuman, mouse, rat
Cited Reactivityhuman, mouse
ClassPolyclonal
TypeAntibody
ImmunogenCatNo: Ag13039 Product name: Recombinant human PDCD1LG2 protein Source: e coli. -derived, PGEX-4T Tag: GST Domain: 1-273 aa of BC074766 Sequence: MIFLLLMLSLELQLHQIAALFTVTVPKELYIIEHGSNVTLECNFDTGSHVNLGAITASLQKVENDTSPHRERATLLEEQLPLGKASFHIPQVQVRDEGQYQCIIIYGVAWDYKYLTLKVKASYRKINTHILKVPETDEVELTCQATGYPLAEVSWPNVSVPANTSHSRTPEGLYQVTSVLRLKPPPGRNFSCVFWNTHVRELTLASIDLQSQMEPRTHPTWLLHIFIPSCIIAFIFIATVIALRKQLCQKLYSSKDTTKRPVTTTKREVNSAI Predict reactive species
Full Nameprogrammed cell death 1 ligand 2
Calculated Molecular Weight273 aa, 31 kDa
Observed Molecular Weight40-50 kDa, 28 kDa
GenBank Accession NumberBC074766
Gene SymbolPD-L2
Gene ID (NCBI)80380
RRIDAB_2878523
ConjugateUnconjugated
Purification MethodAntigen affinity purification
UNIPROT IDQ9BQ51
Storage BufferPBS with 0.02% sodium azide and 50% glycerol, pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20 o C storage. 20ul sizes contain 0.1% BSA.
WB protocol for PD-L2/CD273 antibody 18251-1-APDownload protocol
humanWB J Transl Med Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment. Authors - Zhao-Ying Yang View Article
mouseIHC Cell Rep The hexosamine biosynthetic pathway drives tumor immune evasion via translational control of PD-L1 at the elongation level Authors - Bo Liu View Article
Citations23
DilutionsWB : 1:500-1:2000
IsotypeIgG
ClonalityPolyclonal
Clone Number-
ConjugationUnconjugated

Programmed cell death ligand 2 (PD-L2, also known as CD273, or B7-DC), is one of the B7 family molecules which are type I transmembrane proteins belonging to the immunoglobulin superfamily. PD-L2 was identified both by its homology to PD-L1 and by analysis of genes differentially expressed in libraries generated from dendritic cells (DC) and activated macrophages (PMID: 14515254). PD-L2 is a second ligand for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery. Protocols Product Specific Protocols WB protocol for PD-L2/CD273 antibody 18251-1-AP Download protocol Standard Protocols Click here to view our Standard Protocols

Publications

  1. Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.
    Journal: Aging Cell | Authors: Qixia Xu | Species: human | Application: WB,IHC
  2. The hexosamine biosynthetic pathway drives tumor immune evasion via translational control of PD-L1 at the elongation level
    Journal: Cell Rep | Authors: Bo Liu | Species: mouse | Application: IHC
  3. Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression
    Journal: J Nutr Biochem | Authors: Qi Zhang | Species: human | Application: WB
  4. ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.
    Journal: Cancer Sci | Authors: Keita Katsurahara | Species: human | Application: IHC
  5. IFI30 expression is an independent unfavourable prognostic factor in glioma.
    Journal: J Cell Mol Med | Authors: Xiu Liu | Species: human | Application: IHC
  6. Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.
    Journal: J Transl Med | Authors: Zhao-Ying Yang | Species: human | Application: WB
  7. Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma
    Journal: Front Immunol | Authors: Xianlong Chen | Species: human | Application: IHC
  8. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
    Journal: Oncoimmunology | Authors: Zhi-Liang Wang | Species: human | Application: IHC
  9. Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression
    Journal: J Nutr Biochem | Authors: Qi Zhang | Species: human | Application: WB
  10. ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.
    Journal: Cancer Sci | Authors: Keita Katsurahara | Species: human | Application: IHC
  11. Heat shock proteins related signature characterizes immune status and predicts prognosis of gliomas
    Journal: Sci Rep | Authors: Zhiyan Sun | Species: human | Application: IHC
  12. Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer.
    Journal: Oncol Rep | Authors: Ryota Sumitomo | Species: human | Application: IHC
  13. Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer.
    Journal: Oncol Rep | Authors: Ryota Sumitomo | Species: human | Application: IHC
  14. Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma
    Journal: Biochim Biophys Acta Mol Cell Res | Authors: Yan Liang | Species: mouse | Application: IHC
  15. Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.
    Journal: Antiviral Res | Authors: Tianying Wang | Species: mouse | Application: WB,IHC
  16. LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer
    Journal: Exp Cell Res | Authors: Sishun Gan | Species: human | Application: WB
  17. A New Histology-Based Prognostic Index for Acute Lymphoblastic Leukemia: Preliminary Results of the "ALL Urayasu Classification".
    Journal: J Clin Med | Authors: Toru Mitsumori | Species: human | Application: IHC
  18. A New Histology-Based Prognostic Index for Aggressive T-Cell lymphoma: Preliminary Results of the "TCL Urayasu Classification"
    Journal: J Clin Med | Authors: Hideaki Nitta | Species: human | Application: IHC
  19. A New Histology-Based Prognostic Index for Acute Myeloid Leukemia: Preliminary Results for the "AML Urayasu Classification"
    Journal: J Clin Med | Authors: Toru Mitsumori | Application: IHC
  20. Programmed death-ligand 2 (PD-L2) expression in bladder cancer.
    Journal: Urol Oncol | Authors: Yubo Yang | Species: human | Application: IHC
  21. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
    Journal: Ann Hematol | Authors: Alberto Mussetti | Species: human | Application: IHC
  22. Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report.
    Journal: Anticancer Res | Authors: Kunihiro Asanuma | Species: human
  23. Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy.
    Journal: Eur Surg | Authors: Gerd Jomrich | Species: human | Application: IHC

Product Documents

Datasheet

Reviews

Write Your Own Review
You're reviewing:PD-L2/CD273 Polyclonal antibody 18251-1-AP proteintech
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.